Research Subject Linda Friesen

Phase One trials are now complete and selective stem cell placement (SSCP) has been confirmed as a potential breakthrough therapy for the treatment of Multiple Sclerosis. SSCP is a delivery technology with a demonstrated scienti?c and clinical proof of concept. This is the first time that a potential therapy has strongly demonstrated a return of function for patients. Linda Friesen is one of many study subjects who have had the SSCP therapy and as a result, have recovered function as their lives returned to ‘normalcy’, absent of symptoms and without the need for medications.

Leave a Reply


captcha *